Bone Disease

The Effect of a natural oral nutritional supplement on the level of intra-articular inflammatory mediators in patients with osteoarthritis of the knee (2021) Sharkey P, Shah Z, Gross M, Meade T, Davidoff S, Shohat N, Parvizi J Journal of Orthopaedic Experience and Innovation

IL-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses (2018) van Mens LJJ, van de Sande MGH, Menegatti S, Chen S, Blijdorp ICP, de Jong HM, Fluri IA, Latuhihin TE, van Kuijk AWR, Rogge L, Yeremenko NG, Baeten DLP Arthritis Rheumatol

Phase I/II trial of combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease (2018) Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM Biology of Blood and Marrow Transplantation

Effect of Low-Magnitude, High-Frequency Mechanical Stimulation on Bmd among Young Childhood Cancer Survivors: A Randomized Clinical Trial (2016) Mogil RJ, Kaste SC, Ferry Jr RJ, Hudson MM, Mulrooney DA, Howell CR, Partin RE, Srivastava DK, Robison LL, Ness KK JAMA Oncology

A Phase 2, Randomized, Double-blind, Multicenter Study Comparing Siltuximab Plus Best Supportive Care With Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1?Risk Myelodysplastic Syndrome (2014) Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valc?rcel D, Kranenburg B, Reddy M, Komrokji RS Am J Hematol. 2014 May 31

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (2012) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM N Engl J Med. 2012 Mar;366(9):799-807

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis (2011) Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM Blood. 2011 Jul 1. [Epub ahead of print]

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (2010) Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A N Engl J Med. 363: 1117-27.